Literature DB >> 6367636

Interaction of metronidazole with DNA repair mutants of Escherichia coli.

T C Yeung, B B Beaulieu, M A McLafferty, P Goldman.   

Abstract

It has been proposed that one of metronidazole's partially reduced intermediates interacts either with DNA to exert a bactericidal effect or with water to form acetamide. To test this hypothesis we have examined the effect of metronidazole on several mutants of Escherichia coli that are defective in DNA repair. UV-susceptible RecA- and UvrB- point mutants have an increased susceptibility to metronidazole as manifested by both a decreased minimal inhibitory concentration and a greater bactericidal response to metronidazole in resting cultures. By these criteria, however, we find that UvrB- deletion mutants, which lack the ability to reduce nitrate and chlorate, are no more susceptible to metronidazole than is the wild type. We find, however, that these deletion mutants also lack the ability to reduce metronidazole and thus possibly to form its reactive species. When metronidazole's bactericidal effect is expressed in terms of the concurrent accumulation of acetamide derived from metronidazole, then all RecA- and UvrB- mutants are killed more efficiently than their wild types. The data are consistent, therefore, with metronidazole's lethal effect being mediated by a partially reduced intermediate on the metabolic pathway between metronidazole and acetamide. Defects in other aspects of the DNA repair system do not confer this increased susceptibility to the proposed intermediate. A Tag- mutant, for example, which is defective in 3-methyl-adenine-DNA glycosylase, does not have this increased susceptibility to the presumed precursor of acetamide. Thus, these results provide further support for the hypothesis that the bactericidal effect of metronidazole is mediated by a partially reduced intermediate in the metabolic conversion of metronidazole to acetamide and suggest that this intermediate interacts with DNA to produce a lesion similar to that caused by UV light.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6367636      PMCID: PMC185437          DOI: 10.1128/AAC.25.1.65

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  Mutagenicity of metronidazole: activation by mammalian liver microsomes.

Authors:  H S Rosenkranz; W T Speck
Journal:  Biochem Biophys Res Commun       Date:  1975-09-16       Impact factor: 3.575

2.  Interaction of metronidazole with nucleic acids in vitro.

Authors:  N F LaRusso; M Tomasz; M Müller; R Lipman
Journal:  Mol Pharmacol       Date:  1977-09       Impact factor: 4.436

3.  The mutagenic action of nitroimidazoles. I. Metronidazole, nimorazole, dimetridazole and ronidazole.

Authors:  C E Voogd; J J Van der Stel; J J Jacobs
Journal:  Mutat Res       Date:  1974-12       Impact factor: 2.433

4.  The interaction of reduced metronidazole with DNA.

Authors:  R C Knight; I M Skolimowski; D I Edwards
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

5.  Effect of mutations in deoxyribonucleic acid repair pathways on the sensitivity of Escherichia coli K-12 strains to nitrofurantoin.

Authors:  S T Jenkins; P M Bennett
Journal:  J Bacteriol       Date:  1976-03       Impact factor: 3.490

6.  The reductive metabolism of metronidazole and ronidazole by aerobic liver microsomes.

Authors:  E Perez-Reyes; B Kalyanaraman; R P Mason
Journal:  Mol Pharmacol       Date:  1980-03       Impact factor: 4.436

7.  Escherichia coli mutants deficient in 3-methyladenine-DNA glycosylase.

Authors:  P Karran; T Lindahl; I Ofsteng; G B Evensen; E Seeberg
Journal:  J Mol Biol       Date:  1980-06-15       Impact factor: 5.469

8.  Bacteroides fragilis resistant to metronidazole after long-term therapy.

Authors:  H R Ingham; S Eaton; C W Venables; P C Adams
Journal:  Lancet       Date:  1978-01-28       Impact factor: 79.321

9.  Relationship between metronidazole metabolism and bactericidal activity.

Authors:  E J Chrystal; R L Koch; M A McLafferty; P Goldman
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

10.  The mechanism of action of nitro-heterocyclic antimicrobial drugs. Primary target of 1-methyl-2-nitro-5-vinylimidazole is DNA.

Authors:  B P Goldstein; E Nielsen; M Berti; G Bolzoni; L G Silvestri
Journal:  J Gen Microbiol       Date:  1977-06
View more
  5 in total

1.  Comment on: Identification of antimicrobial activity among FDA-approved drugs for combating Mycobacterium abscessus and Mycobacterium chelonae.

Authors:  Tathagata Mukherjee; Helena Boshoff; Clifton E Barry
Journal:  J Antimicrob Chemother       Date:  2011-10-07       Impact factor: 5.790

Review 2.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

3.  Effect of different nitroheterocyclic compounds on aerobic, microaerophilic, and anaerobic bacteria.

Authors:  H Hof; J Ströder; J P Buisson; R Royer
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

4.  Metronidazole activation and isolation of Clostridium acetobutylicum electron transport genes.

Authors:  J D Santangelo; D T Jones; D R Woods
Journal:  J Bacteriol       Date:  1991-02       Impact factor: 3.490

5.  Click chemistry-facilitated comprehensive identification of proteins adducted by antimicrobial 5-nitroimidazoles for discovery of alternative drug targets against giardiasis.

Authors:  Tineke Lauwaet; Yukiko Miyamoto; Sozaburo Ihara; Christine Le; Jarosław Kalisiak; Keith A Korthals; Majid Ghassemian; Diane K Smith; K Barry Sharpless; Valery V Fokin; Lars Eckmann
Journal:  PLoS Negl Trop Dis       Date:  2020-04-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.